Kevin W. Chamberlin, PharmD
Kevin W. Chamberlin, PharmD, is associate clinical professor and assistant department head, pharmacy practice, University of Connecticut School of Pharmacy, Storrs, Conn.
Meropenem/Vaborbactam for Complicated UTIs
Vabomere combines a carbapenem and a beta-lactamase inhibitor as a treatment for complicated urinary tract infections.
Delafloxacin (Baxdela) for Acute Bacterial Skin Infections
Delafloxacin (Baxdela) for Acute Bacterial Skin Infections
Delafloxacin (Baxdela) for treatment of acute bacterial skin and skin structure infections including cellulitis, wound infection, major cutaneous abscess, and burn infection.
Edaravone (Radicava) for ALS
Edaravone (Radicava) for ALS
Edaravone has been approved for patients with amyotropic lateral sclerosis.
Ocrelizumab for Multiple Sclerosis
Ocrelizumab for Multiple Sclerosis
The FDA has approved ocrelizumab for treating relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.
Safinamide (Xadago): Approved as Add-On for Parkinson’s
Xadago has been approved as a supplementary medication for patients with Parkinson's disease who are having "off" episodes or whose disease is progressing.
Key cogs in the management of Parkinson’s disease
Key cogs in the management of Parkinson’s disease
The goal of this activity is to assist pharmacists in managing difficult-to-treat symptoms of Parkinson’s disease.
FDA approves Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C infection
FDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis.
Daclizumab approved for relapsing forms of multiple sclerosis
Daclizumab is the first subcutaneous injectable monoclonal antibody to be approved for the treatment of MS.
FDA approves brivaracetam for use in partial onset seizure treatment
Brivaracetam provides another adjunctive treatment option for partial onset seizures in patients with uncontrolled epilepsy.
FDA approves PAH treatment
Selexipag is a first-in-class oral treatment option to reduce progression and hospitalization for pulmonary arterial hypertension.